Literature DB >> 2201171

Endothelin causes contraction of canine and bovine arterial smooth muscle in vitro and in vivo.

Y Suzuki1, S Satoh, I Ikegaki, T Asano, M Shibuya, K Sugita, K Lederis, O Rorstad.   

Abstract

We have studied the effect of endothelin, an endothelium-derived peptide, on isolated canine and bovine cerebral arteries in vitro and on canine vertebral blood flow (VBF) in vivo. Endothelin produced a dose-dependent contraction of canine and bovine arterial smooth muscle with ED50 values ranging from 4 to 8 nM. The response to endothelin developed slowly and persisted as a sustained contraction. Maximal contraction by endothelin required the presence of extracellular calcium and was independent of the presence of endothelium. The maximal contraction produced by endothelin was approximately 2-3 times greater than that produced by neuropeptide Y or angiotensin II. The injection of endothelin into the vertebral artery decreased vertebral blood flow (VBF) dose-dependently without affecting systemic blood pressure or heart rate. The decrease in VBF produced by endothelin was long-lasting, like that produced by neuropeptide Y, but more potent. The present data, together with our previous study demonstrating that the intracisternal injection of endothelin induces an unusually long-lasting decrease in the basilar artery diameter angiographically, suggests that endothelin may act as a long-lasting vasoconstrictor in cerebral vascular disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201171     DOI: 10.1007/bf01842892

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  24 in total

1.  [Effect of middle cerebral artery occlusion on serotonin metabolism in rat brain. The correlation with changes of cerebral blood flow and cerebral energy metabolism].

Authors:  T Okada; M Shibuya; Y Suzuki; M Kanamori; M Takayasu; K Ogura; N Kageyama
Journal:  Neurol Med Chir (Tokyo)       Date:  1985-09       Impact factor: 1.742

2.  Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain.

Authors:  Y Kloog; I Ambar; M Sokolovsky; E Kochva; Z Wollberg; A Bdolah
Journal:  Science       Date:  1988-10-14       Impact factor: 47.728

3.  Endothelin induces potent microvascular constriction.

Authors:  S D Brain; J R Tippins; T J Williams
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

4.  Pressure-induced myogenic activation of cat cerebral arteries is dependent on intact endothelium.

Authors:  D R Harder
Journal:  Circ Res       Date:  1987-01       Impact factor: 17.367

5.  Effects of calcitonin gene-related peptide on canine cerebral artery strips and the in-vivo vertebral blood flow in dogs.

Authors:  I Ikegaki; Y Suzuki; S Satoh; T Asano; M Shibuya; K Sugita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

6.  Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization.

Authors:  P A Marsden; N R Danthuluri; B M Brenner; B J Ballermann; T A Brock
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

7.  Effects of neuropeptide Y on canine cerebral circulation.

Authors:  Y Suzuki; M Shibuya; I Ikegaki; S Satoh; M Takayasu; T Asano
Journal:  Eur J Pharmacol       Date:  1988-02-09       Impact factor: 4.432

8.  Leukotriene production in gerbil brain after ischemic insult, subarachnoid hemorrhage, and concussive injury.

Authors:  K J Kiwak; M A Moskowitz; L Levine
Journal:  J Neurosurg       Date:  1985-06       Impact factor: 5.115

9.  Endothelin action: Inhibition by a protein kinase C inhibitor and involvement of phosphoinositols.

Authors:  M Sugiura; T Inagami; G M Hare; J A Johns
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

10.  Endothelin and the production of cerebral vasospasm in dogs.

Authors:  T Asano; I Ikegaki; Y Suzuki; S Satoh; M Shibuya
Journal:  Biochem Biophys Res Commun       Date:  1989-03-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.